Joined in 1996.

Michael Seckl trained in medicine at UCL/UCLH gaining a BSc in immunology in 1983 and his MBBS in 1986. He then obtained his MRCP before entering specialist training in Medical Oncology between 1989-1995.

During this period he spent 3 years at the Imperial Cancer Research Fund (London Research Institute; LRI) working on signal transduction in model and lung cancer cells and was awarded his PhD in 1995 (University of London). He was then appointed as a Senior Lecturer at Imperial College whilst working as a post-doctoral fellow at the LRI enabling a series of successful grant applications to support his ongoing work on drug resistance and metastasis mechanisms in cancer. His clinical appointment also linked him to the national trophoblastic disease service and so, a second stream of research was established.

He is an international leader in trophoblastic disease, past-president and current treasurer of the international trophoblastic disease society (ISSTD.org), president of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD.com), is a visiting Professor at Peking Union Medical College and serves on several editorial boards and grants committees. He leads the gynae theme of the European Rare Adult Cancer (EURACAN) network which aims to improve the care of women with these rare tumours across Europe.

He has chaired/organised many national and international meetings related to trophoblastic disease, lung cancer and cell signalling. He is chair of the London Lung Cancer Alliance. His work is supported by CR-UK, MRC, EU-FP7, AICR, Dept of Health, industry and several other charities. This has resulted in over 240 peer-reviewed publications many appearing in leading clinical and scientific journals. In 2017 he was awarded a Fellowship of the Academy of Medical Sciences (FMedSci).

Joined in 2011.

Dr Paul Nathan received his first medical degree from Cambridge University and qualified in medicine at University College London, both achieved after earlier degrees (including a PhD) specialising in immunology. He was a Fulbright Scholar and carried out his post-doctoral research at the Pittsburgh Cancer Institute in the US. He initially pursued cancer research in academia and in the pharmaceutical industry before finally deciding to pursue a clinical career.

Dr Nathan has a specialist interest in the treatment of renal cell carcinoma (kidney cancer) and melanoma (both uveal and cutaneous). He also has an interest in Merkel Cell Carcinoma. He is currently based at The Mount Vernon Cancer Centre, in Northwood, Middlesex.

He is the first author of the UK guidelines for the systemic treatment of renal cell carcinoma, a member of the National Cancer Research Institute groups for both renal carcinoma and melanoma and is secretary of the UK Melanoma Study Group. He also is a member of the panel currently reviewing the national melanoma guidelines.

Joined in 1985.

Professor Gordon Rustin qualified from the Middlesex Hospital, London in 1971. He was appointed Senior Lecturer in Medical Oncology at the Charing Cross Hospital in 1984 but moved full-time to Mount Vernon Hospital to become Director of Medical Oncology in 1995, where he was leading research and clinical trial of vascular disruptive agents. Professor Rustin is widely published, with over 320 papers to his name on the management of gynaecological cancers, germ cell tumours, the use of tumour markers, and on phase I, II, and III trials. He was awarded an honorary professorship in 2001 by UCL, later becoming the professor of cancer therapy at the Institute of Cancer Research.

He retired from the hospital in 2018 but continues his private practice at BMI Bishops Wood Hospital as well as medico-legal work, refereeing papers and lecturing.

Joined in 2013.

Professor Hall was educated at Cheltenham Ladies College (St Austins 1975-81) and trained in medicine at Guy’s Hospital Medical School. She completed her PhD at the Imperial Cancer Research Fund (now CRUK), working on cyclins and kinases.

Professor Hall is a consultant in medical oncology at Mount Vernon Cancer Centre with her main focus on gynaecological cancers. Professor Hall has been the principal investigator of many clinical trials at Mount Vernon Cancer Centre in this speciality. She is also Chief Investigator of the CeNtuRIOn, CoRINth, and RaNGO trials (nationally). In 2018 she joined translational oncology at Brunel University where she explores the role of circulating cancer-associated cells in gynaecological cancers.

Joined in 2019.

Dr Sharma treats uro-oncological tumours (renal cell carcinoma, bladder cancer, germ cell cancers (testicular/ ovarian) and prostate cancer at Mount Vernon Cancer Centre and Lister Hospital Stevenage. He is involved with adjuvant and metastatic trials in renal cancer and has a special interest in TKI and Immunotherapy. He is also a PI of ongoing renal, urothelial and prostate cancer trials.  He is the lead Acute oncology consultant for the trust.  He has a DPhil in cancer metabolism from the University of Oxford.

Joined in 2022.

Dr. Ehsan Ghorani is a CRUK Clinician Scientist and leads the Cancer Immunology and Immunotherapy Unit within the Division of Cancer at Imperial College London. He completed a PhD on lung cancer immunology with Profs. Sergio Quezada and Charles Swanton at UCL followed by postdoctoral work with Prof. Rafi Ahmed at the Emory Vaccine Centre. His research focusses on understanding how the immune system interacts with cancer and how this knowledge can be translated for patient benefit. This work has contributed to several key discoveries and changed the way patients are treated globally. He has published highly cited work in leading journals, won numerous national and international prizes, served on international grant review committees and is an inventor on two patents.

Joined in 2019.

Dr Pinato leads a translational research programme focusing on the early clinical implementation of novel experimental anticancer therapies to the clinic, with particular emphasis on anti-cancer immunotherapy. He has led the inception of a portfolio of first-in-class studies of immune checkpoint inhibitors in liver cancer, which has represented Dr Pinato’s focus of research since graduation with the highest honours at the University of Piemonte Orientale “A. Avogadro” in Novara, Italy.

He completed his core medical training across some of the busiest acute hospitals in London, being elected member of the Royal College of Physicians (MRCP) in 2014. He has trained in Medical Oncology as part of the Royal Marsden Hospital rotation, having migrated to Imperial College in April 2015 to take up a Clinical Lectureship funded by the National Institute for Health Research (NIHR).

In 2018 Dr Pinato was awarded a Clinician Scientist fellowship funded by the Wellcome Trust Strategic Fund centred on the development of immunotherapy in liver cancer. Additionally, Dr Pinato’s research efforts on biomarker discovery have been recognized with the prestigious Merit Award from the American Society of Clinical Oncology (ASCO) three times in 2016, 2017, 2019 as well as a fourth Merit Award jointly awarded by ASCO and by the Society for Immunotherapy of Cancer (SITC) in 2019. In 2019 Dr Pinato was awarded the prestigious ASCO Global Oncology Young Investigator Award in recognition of his research on HIV-associated hepatocellular cancer.He was also awarded a prize by the British Society of Pharmacology in 2018 and the Sylvia Lawler Prize in Oncology from the Royal Society of Medicine in 2016.

Dr Pinato lectures internationally in the field of molecular oncology with a specific interest in HCC and acts as a reviewer for a number of peer-reviewed journals including Hepatology, Journal of Hepatology, Oncogene, OncoImmunology, Gut and many others. He has acted as a peer reviewer for a number of grant-awarding bodies including the MRC, Breast Cancer Now and Cancer Research UK.

Joined in 2019.

Russell has significantly contributed to the trust’s operations, straightening and optimising our policies and managing risks. Russell is a solicitor partner in the Private Client Group at IBB LAW and brings with him over 33 years of private client experience.

Joined in 2022.

Kiran has a long career in project/programme delivery with a wide range of companies and across several industries. Her most recent experience was as a Programme Director at HSBC leading global projects. She brings her big corporation experience to CTRT, particularly on ensuring we have a clear strategy supported by plans and governance. She works closely with the Charity Manager to keep us focused on priorities both from a fundraising and investment perspective.